Navigation Links
NIH doubles support for vital HIV/AIDS research center
Date:11/1/2007

The National Institutes of Health will award $15 million over the next five years to the Center for AIDS Research of the University of California, San Francisco and the Gladstone Institute for Virology and Immunology to continue its pioneering translational researcha doubling of its previous five-year award.

The UCSF-GIVI Center for AIDS Research is absolutely crucial to maintaining and extending the leadership role of San Francisco in responding to the HIV epidemic. It brings together a true community of HIV investigators who represent the many disciplines and campus sites involved in this effort, said Paul Volberding, MD, the centers co-director and professor and vice-chair, UCSF Department of Medicine and Chief of the Medical Service at the San Francisco Veterans Affairs Medical Center.

Co-directed by Warner Greene, MD, PhD, director of the UCSF affiliated GIVI, the Center for AIDS Research provides strategic, educational and scientific services to HIV/AIDS researchers. Its research goal is to expand the intersections of basic, clinical and behavioral/epidemiological HIV research. It provides infrastructure support to over $80 million of funded HIV/AIDS research at UCSF and affiliated institutions.

CFAR is particularly vital in encouraging the collaborations across conventional scientific disciplines that can direct the amazing expertise of UCSF scientists to address the newest challenges of HIV disease. As we address scientific and clinical challenges here in San Francisco as well as in the world-wide epidemic, CFAR will provide the essential infrastructure to facilitate the most important and innovative science we all depend on, said Greene.

The NIH CFAR program, first funded in 1988, currently supports 19 centers based at leading HIV/AIDS research institutions. UCSF was one of the first institutions to be funded under this program. In 2003, the program was modified to provide greater funding to larger institutions.

The growth plans of CFAR include expanding the number of pilot awards available including funding specific pilots in basic science and for mentoring of foreign scientists. In addition, direct support will be increased for the centers highly successful mentoring program and support for international collaborations, specifically in Eastern Africa.

CFAR provides essential infrastructure for HIV/AIDS research through its clinical and population sciences, immunology (including flow core), virology, specimen bank, and pharmacology cores. These cores provide access to cohorts, assays and services.

CFAR has succeeded in stimulating several advances in HIV/AIDS research, including:

  • Delineating the biology of the APOBEC3G protein in anti-viral immunity

  • Boosting thymic function

  • Changes in viral fitness as a result of antiretroviral drug resistance

  • Understanding the immunopathogenicity of protease inhibitor-resistant HIV

  • In Vivo Assessment of Thymic Function and T-Cell Activation in Patients with Drug-resistant and wild-type HIV

  • Atherosclerosis in HIV Disease

  • Adherence and drug resistance in the United States and Uganda

  • Dissecting the molecular basis of HIV latency

  • Inpatient HIV testing and counseling in Uganda

  • Studies of the interactions between HIV and malaria.


'/>"/>

Contact: Jeff Sheehy
jsheehy@ari.ucsf.edu
415-597-8165
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. Breast cancer risk doubles by high sex hormone levels
2. Down syndrome life anticipation doubles
3. Depression doubles mortality risk after CABG
4. China Doubles Its Investment In AIDS/HIV Treatment.
5. Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy
6. High Carb Diet Doubles Fat Loss
7. Sleep Apnea Doubles Stroke Risk In Elderly
8. Brains pleasure chemical doubles up for pain as well
9. Sight loss risk doubles in overweight people
10. Stroke Risk Nearly Doubles for Siblings of People Who Have Had a Stroke
11. Snacking While Driving Doubles Accident Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer ... for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat ... This sacred and spiritual journey during the Summer Solstice will also be her ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... the Administrative Record, The majority of cases litigated under ERISA involve claims for ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower ... upgrading their training and leads programs. , In February, 2017, Empower Brokerage introduced ... agents, Performance Partners is designed to teach how to maximize their sales efforts, ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of published author, ... his wife, Anna Marie. He and his wife are the proud parents of four ... of “Shadow and Substance.” , “Love, the agape kind, is seen as more than ...
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a total ... & Co., Inc., Biogen and Sanofi are involved in the development of ... which one is in Phase III stage, 15 are in Phase II ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , Latin ... provided for the period 2015 through 2022. Also, a six-year historic analysis ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... Financing Commitment Term Sheet (the "Definitive Financing") it ... of the Company,s stockholders, who are referred to ... a Form 8-K filed with the Securities and ...
Breaking Medicine Technology: